Thiazide-like diuretics
ATC code: C03BA11 (Indapamide)
Inhibits sodium reabsorption at the distal convoluted tubule via the sodium-chloride cotransporter. Beyond its diuretic effect, it has direct vasodilatory action – reduces vascular smooth muscle tone. Metabolically more neutral than hydrochlorothiazide: less impact on glucose, cholesterol, and uric acid levels.
First line
Indapamide is the preferred thiazide-like diuretic per 2024 and . Dose 1.5 mg (sustained release) or 2.5 mg (immediate release) once daily. Antihypertensive efficacy is comparable to amlodipine and ACE inhibitors. Metabolically preferable to – less impact on potassium, glucose, and lipids.
First line
In elderly patients with isolated systolic hypertension, thiazide-like diuretics are first-line. The HYVET trial showed a 30% stroke reduction and 21% all-cause mortality reduction with indapamide (with possible perindopril addition) in patients over 80. The PROGRESS trial confirmed reduced recurrent stroke risk with indapamide plus perindopril.
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
Indapamide is a thiazide-like diuretic. It is prescribed for hypertension ( 2023, SEH-LELHA). In alt detox circles, indapamide is occasionally promoted to remove excess fluid in people with normal blood pressure. In people without hypertension, no clinical studies of such use exist; a diuretic in healthy people causes volume imbalance. The drug has specific risks: hypokalemia, hyponatremia (especially in older adults, sometimes severe, described after several weeks of use), hyperuricemia with gout flare risk, elevated glucose and lipids, and photosensitivity. If indapamide was prescribed for detox in a healthy person, consider seeking a second opinion.
7 pairs found. Sorted from critical to minor.
Mechanism
Indapamide (thiazide-like diuretic) increases potassium and magnesium loss. Low levels amplify amiodarone's QT-prolonging effect.
Symptoms
QT prolongation on ECG. Clinically: dizziness, syncope, palpitations. Severe cases progress to polymorphic ventricular tachycardia (torsades de pointes) with risk of ventricular fibrillation and sudden cardiac death. Risk is higher with hypokalaemia, hypomagnesaemia, bradycardia, and ischaemic heart disease.
Management
The combination is common (hypertension plus atrial fibrillation). Check potassium and magnesium every 3 months; if potassium drops below 4.0 mmol/L, add a potassium-sparing diuretic or potassium supplement.
Mechanism
Indapamide (thiazide-like diuretic) increases urinary potassium loss. Low potassium amplifies dronedarone's QT effect.
Symptoms
QT prolongation on ECG. Dizziness, syncope, palpitations. Severe cases: polymorphic ventricular tachycardia (torsades de pointes). Risk is higher with hypokalaemia and hypomagnesaemia.
Management
The combination is common (hypertension + atrial fibrillation). Check potassium and magnesium every 3 months; if potassium drops below 4.0 mmol/L, add a potassium-sparing diuretic or potassium supplement.
Mechanism
Indapamide is a thiazide-like diuretic. The lithium-raising mechanism is the same as hydrochlorothiazide: enhanced lithium reabsorption in the proximal tubules via subclinical volume depletion. Serum lithium rises.
Symptoms
Tremor, muscle twitching, nausea, diarrhoea, confusion, ataxia. Severe cases include seizures, coma, and nephrogenic diabetes insipidus with dehydration. Symptoms emerge when serum lithium exceeds 1.2 mmol/L.
Management
Reduce lithium dose by 25–30% when starting indapamide; check serum lithium at 1 week, then monthly. Alternatives: amlodipine or a beta-blocker without lithium effects.
Mechanism
Indapamide (thiazide-like diuretic) raises allopurinol and oxypurinol levels, increasing hypersensitivity risk. The effect is weaker than with hydrochlorothiazide but clinically significant in older patients and chronic kidney disease.
Symptoms
Rash, fever, facial oedema, lymphadenopathy, abnormal liver function. Reactions develop 2–8 weeks after starting allopurinol.
Management
Dose allopurinol by creatinine clearance (start 100 mg/day if clearance below 60 mL/min). In Asian patients, HLA-B*58:01 testing is recommended. In significant hyperuricaemia, replacing indapamide with losartan lowers uric acid by 10–15%.
Mechanism
Additive hypotension and fall risk in older patients. Additional delirium risk with diuretic-induced hypovolaemia.
Symptoms
Lower blood pressure, postural dizziness, fatigue. Older patients: fall risk.
Management
In older patients, check standing and sitting blood pressure 1–2 weeks after start; assess fluid and electrolyte balance. Alternative anxiolytic: hydroxyzine or a short lorazepam course.
Mechanism
Additive orthostatic hypotension and hypokalaemia risk. Older patients: delirium risk with thiazide-like diuretic hypovolaemia.
Symptoms
Postural dizziness, syncope, fatigue. Older patients: fall and fracture risk.
Management
In older patients, check standing and sitting blood pressure, assess potassium and sodium. For neuropathic pain, alternative: gabapentin or pregabalin.
Mechanism
Standard combination in hypertension – additive antihypertensive effect. Indapamide (thiazide-like diuretic) causes hypokalaemia.
Symptoms
Lower blood pressure, postural dizziness, fatigue. Older patients: fall risk. With additional antihypertensives: bradycardia (pulse below 60/min).
Management
Standard combination. Check potassium 2–4 weeks after start and then annually. If potassium drops below 4.0 mmol/L, add a potassium-sparing component.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Direct links to regulator labels. Open in a new tab.
FDA category B. However, diuretics in general are not recommended in pregnancy as they may reduce uteroplacental blood flow. Not a drug of choice in pregnancy. Methyldopa, labetalol, and nifedipine are preferred.
Limited data on excretion in breast milk. Diuretics may reduce lactation. Not prescribed to breastfeeding mothers unless essential.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Indapamide is evaluated for the following indications with varying evidence strength: Isolated systolic hypertension in the elderly (evidence tier A), Hypertension (evidence tier A), Body detoxification and cleansing (evidence tier F). See the full indication matrix with dosing and citations above on this page.
Common side effects of Indapamide (≥ 1 in 100): Hypokalemia (less common than with hydrochlorothiazide), Hyponatremia, Hyperuricemia, Dizziness, orthostatic hypotension. See the Safety section for uncommon and serious reactions.
FDA category B. FDA category B. However, diuretics in general are not recommended in pregnancy as they may reduce uteroplacental blood flow. Not a drug of choice in pregnancy. Methyldopa, labetalol, and nifedipine are preferred.
Limited data on excretion in breast milk. Diuretics may reduce lactation. Not prescribed to breastfeeding mothers unless essential.
Indapamide is contraindicated in: Severe renal impairment (eGFR below 30) – loses efficacy; Severe hepatic impairment, hepatic encephalopathy; Hypokalemia; Hypersensitivity to sulfonamides. Full list in the Safety section.